Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports and stock price the company's current number of shares outstanding is 145,600,000. At the end of 2024 the company had 145,600,000 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.